Medicare and Medicaid would cover weight-loss drugs like Wegovy and Ozempic under a new rule proposed by President Joe Biden on Tuesday, increasing access to the widely popular medications to millions of adults with obesity in the U.S., though the plan would likely face opposition under President-elect Donald Trump's second administration.

The proposal would expand coverage of anti-obesity drugs to 7.5 million people covered by Medicare and Medicaid, the Biden administration said.

The Biden-Harris administration proposed a new rule on Tuesday that would expand coverage of the anti-obesity medications known as GLP-1 treatments for Medicare and Medicaid beneficiaries. Medicare is currently only allowed to cover these medications for weight loss if they are prescribed to treat a second condition as well.

Medicare and Medicaid would be required to cover weight loss drug prescriptions for millions of obese Americans under plans announced by the Biden administration Tuesday.

Millions of obese Americans would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by Medicare or Medicaid under a new rule the Biden administration proposed Tuesday morning.

The plans from the Department of Health and Human Services come on the heels of criticism Ozempic and other weight loss medications received by RFK Jr.

The Biden administration is proposing a rule that would require the US government to cover obesity drugs for millions of Americans, teeing up a financial and political challenge for President-elect Donald Trump as he prepares to take office.

Under a new proposal from President Biden, weight loss drugs would be covered by Medicare and Medicaid. NBC News medical contributor Dr. Natalie Azar joins José Díaz-Balart to provide insight on who would benefit from the expanded coverage and what the approval process would look like.